Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 2:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: prior authorization Clear all
Recruiting No phase listed Observational

A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders

NCT06092346
View directory record Official record
Conditions
AMPD3, OMIM*102772, AMP Deaminase Deficiency, AK1, OMIM *103000, Adenylate Kinase Deficiency, AMPD1, OMIM *102770, Myopathy Due to Myoadenylate Deaminase Deficiency, TPMT, OMIM *187680, Thoipurines, Poor Metabolism of, IMPDH1, OMIM *146690, Retinitis Pigmentosa Type 10, Leber Congenital Amauriosis Type 11, APRT, OMIM *102600, Adenine Phosphoribosyltransferase Deficiency, HPRT1, OMIM *308000 Lesch-Nyhan Disease, XDH, OMIM *607633, Xanthinuria Type 1, SLC2A9, OMIM *606142 Hypouricemia, SLC22A12, OMIM *607096 Hypouricemia, PRPS1 Def, OMIM *311850, Arts Syndrome; Charcot-Marie-Tooth Disease, PRPS1 SA, OMIM *311850 Gout, PRPS-related Phosphoribosylpyrophosphate Synthetase Superactivity, AMPD2, OMIM *102771, Spastic Paraplegia 63; Pontocerebellar Hypoplasia, ITPA, OMIM *147520, Inosine Triphosphatase Deficiency; Developmental and Epileptic Encephalopathy 35, ADSL, OMIM *608222, Adenylosuccinate Lyase Deficiency, PNP, OMIM *164050, Nucleoside Phosphorylase Deficiency, ADA2, OMIM *607575,Sneddon Syndrome; VAIHS, CAD, *1140120, Developmental and Epileptic Encephalopathy, UPB1, OMIM *606673, Beta-ureidopropionase Deficiency, DPYS, OMIM *613326, Dihydropyrimidinase Deficiency, DPYD, OMIM *274270, Dihydropyrimidine Dehydrogenase Deficiency, DHODH, OMIM *126064, Miller Syndrome (Postaxial Acrofacial Dysostosis), UMPS, OMIM *613891, Orotic Aciduria, NT5C3A<TAB>, OMIM *606224, Anemia, Hemolytic, Due to UMPH1 Deficiency, UNG, OMIM *191525, Hyper-IgM Syndrome 5, AICDA, OMIM *605257, Immunodeficiency With Hyper-IgM, Type 2; HIGM2, Purine-Pyrimidine Metabolism, Metabolic Disease
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Month to 100 Years
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2099
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 15, 2026, 2:04 PM EDT
Completed Not applicable Interventional Results available

Breast Cancer Risk Reduction: A Patient Doctor Intervention

NCT01830933
View directory record Official record
Conditions
Breast Cancer
Interventions
BreastCARE
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 74 Years
Enrollment
1,235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Sep 15, 2026, 2:04 PM EDT
Terminated No phase listed Observational

Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study

NCT01280747
View directory record Official record
Conditions
Fibromyalgia, Painful Diabetic Peripheral Neuropathy
Interventions
prior authorization, no prior authorization
Other
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
17
States / cities
Beverly Hills, California • Lomita, California • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Sep 15, 2026, 2:04 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency

NCT01371825
View directory record Official record
Conditions
Lysosomal Acid Lipase Deficiency, Wolman Disease
Interventions
Sebelipase alfa (SBC-102)
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Up to 24 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Sep 15, 2026, 2:04 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma

NCT03410693
View directory record Official record
Conditions
Carcinoma, Transitional Cell
Interventions
Rogaratinib (BAY1163877), Chemotherapy
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
16
States / cities
Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 15, 2026, 2:04 PM EDT
Completed No phase listed Observational

Multiplex Testing for Breast Cancer Susceptibility: A Pilot Study of Subject Preferences for Information and Responses After Testing

NCT01992471
View directory record Official record
Conditions
Breast Cancer
Interventions
Pre-test Assessment, Pre test Counseling, Blood draw, Post-test counseling, and post-test assessment, Follow-up assessments (6 and 12 months)
Behavioral · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Sep 15, 2026, 2:04 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients

NCT05286242
View directory record Official record
Conditions
Multiple Sclerosis, Autoimmune Blistering Disease, B-Cell Deficiency
Interventions
COVID19 vaccine
Biological
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 15, 2026, 2:04 PM EDT
Recruiting No phase listed Observational

Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG

NCT05672615
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Cancer
Interventions
Questionnaires, Daily Mood Diaries, Urine Specimen Collection, Research Blood Draw, Utilize excess tissue from a standard of care procedure
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 15, 2026, 2:04 PM EDT
Completed Not applicable Interventional Results available

The Impact of Sharing Audio Recorded Clinic Visits on Self-management in Older Adults

NCT04344301
View directory record Official record
Conditions
Diabetes Mellitus, Hypertension
Interventions
Audio recording
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
65 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Manchester, New Hampshire • Nashville, Tennessee • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Sep 15, 2026, 2:04 PM EDT
Completed Phase 3 Interventional

A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria

NCT05166161
View directory record Official record
Conditions
Phenylketonuria
Interventions
PTC923
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
Not listed
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Aurora, Colorado • Gainesville, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 15, 2026, 2:04 PM EDT
Recruiting Not applicable Interventional

Environmental and Sensory Intervention for Nursing Home Residents With Dementia Who Exhibit Persistent Vocalizations

NCT06568107
View directory record Official record
Conditions
Dementia
Interventions
Environmental And Sensory Experience (EASE) intervention
Behavioral
Lead sponsor
Drexel University
Other
Eligibility
50 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Sep 15, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

NCT01336634
View directory record Official record
Conditions
Cancer
Interventions
Dabrafenib, Trametinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
15
States / cities
Los Angeles, California • Orange, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 15, 2026, 2:04 PM EDT
Recruiting Not applicable Interventional

Strategies to AchieVe Viral Suppression for Youth With HIV

NCT06886971
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV) Infection
Interventions
The SAVVY intervention includes CHOICE counseling and shared decision-making regarding ART preference (informed by the evidence-based HIV-ASSIST) and facilitating LA-ART access
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years to 30 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 15, 2026, 2:04 PM EDT
Enrolling by invitation Not applicable Interventional

AI-Supported Care Engagement for Next-step Delivery - Medicare Advantage

NCT07804095
View directory record Official record
Conditions
Population Health Management, Patient Navigation
Interventions
AI-Supported Rising-Risk Care Navigation
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
9,906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 15, 2026, 2:04 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effectiveness of the Consent Process

NCT00630136
View directory record Official record
Conditions
Parental Consent
Interventions
interview
Behavioral
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 23, 2010 · Synced Sep 15, 2026, 2:04 PM EDT
Terminated Phase 3 Interventional Results available

A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide

NCT03495921
View directory record Official record
Conditions
Ewing Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Ewing's Tumor Recurrent, Rare Diseases, Sarcoma, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective Tissue, Sarcoma, Ewing, Neoplasms
Interventions
Vigil, Irinotecan, Temozolomide
Biological · Drug
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
2 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
15
States / cities
Little Rock, Arkansas • Los Angeles, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Sep 15, 2026, 2:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Building an Evidence Base for Weight Loss Strategies Among Those With Chronic SCI-The GLB-SCI+

NCT03874988
View directory record Official record
Conditions
Spinal Cord Injuries, Obesity, Weight Loss, Diet Modification
Interventions
Portion-Controlled Meals, Enhanced Self-Monitoring, GLB-SCI+
Behavioral
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 15, 2026, 2:04 PM EDT
Recruiting No phase listed Observational

Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients

NCT02530658
View directory record Official record
Conditions
Solid, Liquid, Central Nervous System Tumors
Interventions
Study Introduction Visit, Informed Consent Visit, Informed Consent Follow-Up Visit, Return of Results Conversation, Return of Results Follow-Up Visits, Blood Sample, Skin Biopsy
Other · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2053
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 15, 2026, 2:04 PM EDT
Recruiting Not applicable Interventional

Transplanting Lungs From Uncontrolled Donation After Circulatory Death

NCT06327945
View directory record Official record
Conditions
Lung Transplantation
Interventions
Lung uDCD Protocol
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Sep 15, 2026, 2:04 PM EDT
Recruiting Not applicable Interventional

Weight Bias Reducation Intervention With Nursing Students Using Simulation: The BRAVE Study

NCT07334470
View directory record Official record
Conditions
Weight Bias
Interventions
BRAVE, SOL: Standard Obesity Lecture
Behavioral
Lead sponsor
Villanova University
Other
Eligibility
18 Years to 35 Years
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Villanova, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 15, 2026, 2:04 PM EDT
Recruiting Not applicable Interventional

Computerized Decision Support for Prevention of VTE in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT)

NCT03728166
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Electronic alert
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 15, 2026, 2:04 PM EDT
Terminated Not applicable Interventional

Cryotherapy in Preventing Peripheral Neuropathy and Nail Toxicity in Patients With Breast Cancer Who Are Receiving Paclitaxel

NCT01243541
View directory record Official record
Conditions
Chemotherapeutic Agent Toxicity, Pain, Peripheral Neuropathy, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Therapy-related Toxicity
Interventions
cryotherapy, questionnaire administration, quality-of-life assessment, management of therapy complications, assessment of therapy complications
Procedure · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 15, 2026, 2:04 PM EDT
Active, not recruiting No phase listed Observational

X-linked Hypophosphatemia Disease Monitoring Program

NCT03651505
View directory record Official record
Conditions
X-linked Hypophosphatemia, Hypophosphatemic Rickets
Interventions
No intervention
Other
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
Not listed
Enrollment
782 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2032
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 15, 2026, 2:04 PM EDT
Available No phase listed Expanded access

Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping

NCT07250737
View directory record Official record
Conditions
Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, Inborn, Genetic Diseases, X-Linked, Muscular Dystrophies, Muscular Dystrophy, Duchenne
Interventions
delpacibart zotadirsen
Drug
Lead sponsor
Avidity Biosciences, Inc.
Industry
Eligibility
2 Years and older · Male only
U.S. locations
21
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Irvine, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 15, 2026, 2:04 PM EDT